Jingdong Zhang - Concepedia

Author

Jingdong Zhang

Also Known As

J D Zhang, J.‐M. Zhang, Jierer Ying, Jing-Dong Zhang, Jing-dong ZHANG, Jing-dong Zhang, Jingdong Zhang, Li Bai, Liangming Zhang, Tao Yu

236

Publications

4.8K

Citations

H-Index

Concepts

All Affiliations

China Medical University Liaoning Cancer Hospital & Institute First Hospital of China Medical University Harbin Medical University Third Affiliated Hospital of Harbin Medical University

About

Jingdong Zhang is an author at China Medical University specializing in medicine, cancer research, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	23	1.3K
2	Cell Biology	9	9	543
3	Health Sciences	2	2	279
4	Natural Sciences	2	2	82
5	Biochemistry	2	2	39

Jingdong Zhang

Publications

Citations

H-Index

Page 1

	Year	Citations
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer Jianming Xu, Haiping Jiang, Yueyin Pan, JAMA	2023	300
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study Jianming Xu, Ken Kato, Eric Raymond, The Lancet Oncology Chemotherapy Versus PlaceboEsophageal CancerGastrointestinal OncologyMedicineClinical Trials	2023	248
PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells Dan Li, Xiujuan Qu, Kezuo Hou, Anti-Cancer Drugs Gastric Cancer CellsCell RegulationHuman LeukemiaBufalin Induces ApoptosisChemoprevention Strategy	2008	157
How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy. Yiming Ma, Qiwei Wang, Qian Dong, PubMed Cancer ManagementImmunologyImmunoeditingPathologyImmunotherapeutics	2019	152
First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial Yan Song, Bo Zhang, Dao Xin, Nature Medicine	2023	149
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2) Jianming Xu, Yi Li, Qingxia Fan, Nature Communications	2022	147
β-Elemene-induced autophagy protects human gastric cancer cells from undergoing apoptosis Jing Liu, Ye Zhang, Jinglei Qu, BMC Cancer	2011	136
Oxaliplatin enhances TRAIL‐induced apoptosis in gastric cancer cells by CBL‐regulated death receptor redistribution in lipid rafts Ling Xu, Xiujuan Qu, Ye Zhang, FEBS Letters Gastric Cancer CellsOncologyLipid RaftsGastrointestinal OncologyMedicine	2009	75
The Wnt/β-catenin pathway drives increased cyclin D1 levels in lymph node metastasis in papillary thyroid cancer Jingdong Zhang, Anthony J. Gill, Joseph D. Issacs, Human Pathology Wnt/β-catenin Pathway DrivesTumor BiologyMedicinePapillary Thyroid CancerThyroid Disease	2011	71
First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: <scp>CheckMate</scp> 649 Chinese subgroup analysis Tianshu Liu, Yuxian Bai, Xiaoyan Lin, International Journal of Cancer Surgical OncologyEsophageal CancerCancer ManagementGastroenterologyPathology	2022	66

Page 1